Back to News
Market Impact: 0.25
Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Teva reported positive topline Phase 2a results for TEV-408, its investigational anti-IL-15 monoclonal antibody, in adults with celiac disease. The update is supportive for the program’s development outlook, though no efficacy/magnitude details were provided in the article.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
TEVA0.45
More News
- Christine Lagarde: IMFC Statement
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test